Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii

International Journal of Antimicrobial Agents

Volumn 48, Issue 3, 2016, Pages 331-336

  Rao, Gauri G ^a   Ly, Neang S ^b   Diep, John ^a   Forrest, Alan ^c   Bulitta, Jürgen B ^d   Holden, Patricia N ^a   Nation, Roger L ^e   Li, Jian ^e   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MEDIMMUNE   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Acinetobacter baumannii; Combinations; Pharmacodynamics; Polymyxin B; Polymyxins; Tigecycline

Indexed keywords

CARBAPENEM; COLISTIN; MEROPENEM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; TIME FACTOR;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MINOCYCLINE; POLYMYXIN B; TIME FACTORS;

EID: 84984850920     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.06.006     Document Type: Article

References (18)

1. [1] Peleg, A.Y., Adams, J., Paterson, D.L., Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007), 2065–2069.
2. [2] Pogue, J.M., Lee, J., Marchaim, D., Yee, V., Zhao, J.J., Chopra, T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53 (2011), 879–884.
3. [3] Peleg, A.Y., Potoski, B.A., Rea, R., Adams, J., Sethi, J., Capitano, B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59 (2007), 128–131.
4. [4] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. 2005, CLSI, Wayne, PA Document M100-S15.
5. [5] Bergen, P.J., Forrest, A., Bulitta, J.B., Tsuji, B.T., Sidjabat, H.E., Paterson, D.L., et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55 (2011), 5134–5142.
6. [6] Begic, D., von Eiff, C., Tsuji, B.T., Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J Antimicrob Chemother 63 (2009), 977–981.
7. [7] Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S., Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005), 220–229.
8. [8] Pillai, S.K., Moellering, R.C. Jr, Eliopoulos, G.M., Antimicrobial combinations. Lorian, V., (eds.) Antibiotic in laboratory medicine, 5th ed, 2005, Lippincott Williams & Wilkins, Philadelphia, PA, 365–440.
9. [9] Center for Disease Dynamics, Economics and Policy, ResistanceMap. Multidrug-resistant Acinetobacter baumannii. Washington, DC; Center for Disease Dynamics, Economics and Policy http://resistancemap.cddep.org/ accessed 08.07.16.
10. [10] Hagihara, M., Housman, S.T., Nicolau, D.P., Kuti, J.L., In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 58 (2014), 874–879.
11. [11] Moland, E.S., Craft, D.W., Hong, S.G., Kim, S.Y., Hachmeister, L., Sayed, S.D., et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline–amikacin synergy. Antimicrob Agents Chemother 52 (2008), 2940–2942.
12. [12] Yilmaz, E.M., Sunbul, M., Aksoy, A., Yilmaz, H., Guney, A.K., Guvenc, T., Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 40 (2012), 332–336.
13. [13] Rao, G.G., Ly, N.S., Haas, C.E., Garonzik, S., Forrest, A., Bulitta, J.B., et al. New dosing strategies for an ‘old’ antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics of patients with kidney or liver disease. Antimicrob Agents Chemother 58 (2014), 1381–1388.
14. [14] Mohamed, A.F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56 (2012), 4241–4249.
15. [15] Xie, J., Wang, T., Sun, J., Chen, S., Cai, J., Zhang, W., et al. Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Int J Infect Dis 18 (2014), 62–67.
16. [16] Cheng, A., Chuang, Y.C., Sun, H.Y., Sheng, W.H., Yang, C.J., Liao, C.H., et al. Excess mortality associated with colistin–tigecycline compared with colistin–carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med 43 (2015), 1194–1204.
17. [17] Chuang, Y.-C., Cheng, C.-Y., Sheng, W.-H., Sun, H.-Y., Wang, J.-T., Chen, Y.-C., et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 14 (2014), 1–8.
18. [18] Falagas, M.E., Vardakas, K.Z., Tsiveriotis, K.P., Triarides, N.A., Tansarli, G.S., Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 44 (2014), 1–7.